Big Pharma Split Corp.
PRM.TO
TSX
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 854.80K | 190.80K | -478.60K | -328.20K | -172.40K |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.36M | 5.33M | 9.27M | 9.00M | 8.73M |
| Change in Net Operating Assets | 19.70K | 13.50K | 7.20K | 24.40K | 42.40K |
| Cash from Operations | 2.23M | 5.53M | 8.80M | 8.69M | 8.60M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | 0.00 | 0.00 |
| Repurchase of Common Stock | -831.00K | -3.08M | -5.32M | -4.92M | -4.52M |
| Issuance of Preferred Stock | 1.05M | 748.20K | 445.20K | 388.40K | 331.60K |
| Repurchase of Preferred Stock | 0.00 | -2.74M | -5.49M | -5.49M | -5.49M |
| Total Dividends Paid | -1.51M | -1.54M | -1.56M | -1.68M | -1.82M |
| Other Financing Activities | -- | -- | -- | 0.00 | 0.00 |
| Cash from Financing | -1.35M | -5.32M | -9.25M | -9.12M | -8.99M |
| Foreign Exchange rate Adjustments | 0.00 | -1.00K | -1.90K | -1.50K | -1.10K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 879.30K | 214.90K | -456.00K | -422.70K | -389.80K |
